Colgate-Palmolive (NYSE:CL) Price Target Reduced to $77.00



Colgate-Palmolive (NYSE:CL – Get Note) saw its target price lowered by Barclays from $81.00 to $77.00 in a research report published on Tuesday, reports The Fly. Barclays’ price target would suggest a potential upside of 2.42% from the company’s previous close.

Other equity research analysts have also recently released reports on the company. Morgan Stanley raised its price target on Colgate-Palmolive from $90.00 to $91.00 and gave the stock an “equal weight” rating in a research report on Monday, Jan. 31. Atlantic Securities downgraded Colgate-Palmolive from an “overweight” rating to a “neutral” rating and lowered its target price for the stock from $92.00 to $80.00 in a research report Tuesday. Citigroup raised its price target on Colgate-Palmolive from $83.00 to $86.00 and gave the stock a “neutral” rating in a Monday, January 31 research report. Sanford C. Bernstein upgraded Colgate-Palmolive from an “underperforming” rating to a “market performing” rating and raised its share price target from $77.00 to $83.00 in a research report from Wednesday, February 2. Finally, StockNews.com upgraded Colgate-Palmolive shares from a “buy” rating to a “hold” rating in a Wednesday, April 13 research note. Two research analysts rated the stock with a sell rating, thirteen gave the company a hold rating and three gave the company a buy rating. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $85.56.

NYSE:CL shares opened at $75.18 on Tuesday. The company’s fifty-day moving average is $77.32 and its two-hundred-day moving average is $79.07. The company has a quick ratio of 0.67, a current ratio of 1.10 and a debt ratio of 10.45. Colgate-Palmolive has a 12-month low of $72.20 and a 12-month high of $85.61. The company has a market capitalization of $63.20 billion, a P/E ratio of 31.07, a price-to-earnings growth ratio of 3.79 and a beta of 0.56.

Colgate-Palmolive (NYSE:CL – Get Rating) last reported results on Friday, April 29. The company reported earnings per share (EPS) of $0.74 for the quarter, matching the consensus estimate of $0.74. Colgate-Palmolive achieved a net margin of 11.70% and a return on equity of 296.77%. The company posted revenue of $4.40 billion for the quarter, versus a consensus estimate of $4.40 billion. During the same period of the previous year, the company achieved EPS of $0.80. The company’s revenue increased 1.3% year over year. Equity research analysts expect Colgate-Palmolive to post earnings per share of 3.25 for the current year.

Colgate-Palmolive announced that its board of directors on Thursday (March 10) approved a stock repurchase program that allows the company to repurchase $5.00 billion in stock. This repurchase authorization allows the company to repurchase up to 8.1% of its shares through open market purchases. Stock buyback programs are often a sign that a company’s board believes its stock is undervalued.

In other Colgate-Palmolive news, Director John P. Bilbrey sold 4,917 Colgate-Palmolive shares in a trade on Monday, February 14. The shares were sold at an average price of $78.66, for a total transaction of $386,771.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this link. Additionally, director John T. Cahill sold 5,389 shares of the company in a trade on Thursday, February 3. The shares were sold at an average price of $83.16, for a total transaction of $448,149.24. The disclosure of this sale can be found here. Insiders sold a total of 127,080 shares of the company valued at $10,443,094 in the past ninety days. Insiders of the company own 0.31% of the shares of the company.

Hedge funds have recently changed their positions in the business. Horan Securities Inc. acquired a new position in shares of Colgate-Palmolive in Q4 worth $30,000. TAP Consulting LLC acquired a new position in shares of Colgate-Palmolive in Q4 worth $40,000. Widmann Financial Services Inc. acquired a new position in shares of Colgate-Palmolive in Q4 worth $42,000. Riverview Trust Co bought a new stake in Colgate-Palmolive in Q1 worth $38,000. Finally, Shore Point Advisors LLC purchased a new stake in Colgate-Palmolive in Q4 for $43,000. 78.12% of the shares are held by institutional investors.

Colgate-Palmolive Company Profile (Get a rating)

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The Company operates through two segments, Oral, Personal and Home Care; and animal nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwashes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin care products, dishwashing detergents, fabric conditioners, household cleaners and other related items.

Featured Articles

The Fly logo

Analyst Recommendations for Colgate-Palmolive (NYSE: CL)



Get news and reviews for Colgate-Palmolive Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Colgate-Palmolive and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous How American Toy Makers and Publishers Created an Alternative Jewish Universe
Next 2022 Sable Secure Card Review